The Daily Toke

March 24, 2026

Federal cannabis coverage expansion comes as political battles over legalization intensify across multiple states, creating a patchwork of competing policy frameworks that reveals deep partisan divides over how—and whether—to regulate the plant.

The Centers for Medicare & Medicaid Services released the first official details about a pilot program launching April 1 that will provide insurance coverage for hemp-derived CBD products, confirming that up to 3 milligrams of THC will be allowed. 🚀 THIS IS COOL The move marks the first time the federal government has directly covered cannabis-derived products through Medicare, a significant shift in how the nation treats plant-based medicine. However, the timeline remains uncertain: President Donald Trump recently signed a law to recriminalize hemp THC products, which could eliminate the program before it fully launches if implementation moves without delay. Meanwhile, Congress is grinding through 16 separate cannabis bills in the 2025-2026 session, with the MORE Act leading at 62 sponsors, while other proposals ranging from the STATES 2.0 Act to the CLIMB Act represent competing visions of federal cannabis policy—some favoring full descheduling, others protecting state autonomy, and still others shielding cannabis businesses from federal interference.

💰 MONEY MOVES Pennsylvania Gov. Josh Shapiro is projecting $729 million in new revenue next fiscal year if lawmakers legalize recreational marijuana, a figure that has anchored his budget proposal for two consecutive years. Yet the state remains deadlocked over a fundamental question: which government agency should oversee the market? Republican Sen. Dan Laughlin is pushing for a new Cannabis Control Board to manage both medical and recreational cannabis, while Democratic Rep. Dan Frankel advocates placing it under the existing Liquor Control Board—the same approach that passed the House last year only to be rejected by Laughlin's Senate committee. Frankel signaled openness to discussion ("I never say never"), but Laughlin made clear the new board is a prerequisite for any legalization passing this year. A third faction, led by Republican Rep. Kathy Rapp, opposes legalization entirely, citing concerns about youth addiction, impaired driving, and mental health effects—arguments supported by a JAMA study showing 10 to 30 percent of users develop cannabis use disorder. The gridlock illustrates a pattern: states want the tax revenue, but can't agree on the regulatory structure to capture it.

Meanwhile, states that already legalized cannabis are now rolling back provisions and tightening restrictions. Ohio's new marijuana laws took effect March 20, rolling back key consumer freedoms voters approved just two years prior: intoxicating hemp products are now illegal again, extract potency is capped at 70% THC (down from 90%), sharing is restricted to 2.5 ounces per day, out-of-state purchases are prohibited, and workers fired for cannabis use are ineligible for unemployment benefits. Massachusetts faces a ballot initiative seeking to essentially repeal the 2016 legalization that voters passed by significant margin, with the Coalition for a Healthy Massachusetts arguing the state has become uncomfortable—citing visibility of cannabis use in public spaces—though legislators pointed out the proposed rollback would still allow adults to gift up to an ounce, potentially creating the black market the measure claims to address. Meanwhile, Georgia lawmakers passed a bill expanding medical cannabis access with vaping options and higher THC limits, Utah's Republican governor signed legislation supporting psychedelic-assisted therapy clinical trials for veterans, and Minnesota advanced a bill allowing hemp producers to continue out-of-state testing.

🤔 THINK ABOUT IT The contradiction is stark: federal Medicare coverage now recognizes hemp-derived cannabinoids as medically valuable, yet the Trump administration simultaneously pushes to recriminalize hemp THC. Colorado's cannabis retailers achieved a 99 percent compliance rate on age verification, suggesting regulated markets actually work to prevent youth access. New Mexico is funding psilocybin therapy access for low-income patients. Canadian Conservative Leader Pierre Poilievre told Joe Rogan marijuana should be a "personal choice," despite voting against legalization. Yet in Ohio, voters' democratic choice to legalize was substantially gutted by the same legislature that just approved it. The divergence between federal recognition of cannabis therapeutics, state-level legalization momentum, and simultaneous legislative rollbacks suggests the real debate isn't about science or safety—it's about control, revenue, and which institutions get to decide.

March 24, 2026

Texas will ban smokeable hemp products effective March 31, joining a growing wave of states rolling back cannabis access even as public policy increasingly contradicts documented safety data. The Texas Department of State Health Services released regulations this month that eliminate natural smokeable hemp—including pre-rolled joints and hemp flower—while simultaneously tripling retail registration fees from $155 to $5,000 and hiking manufacturer licensing costs from $258 to $10,000 per facility. Industry executives argue the fee structure is a de facto ban designed to force closures. "They did a ban with their own regulatory scheme," said Lukas Gilkey, CEO of Hometown Hero, a major hemp manufacturer. "The way they wrote the rules, it's going to eliminate a lot of products that are fully legal and fully fine and not harmed anyone." 💰 MONEY MOVES Heather Fazio, director of the Texas Cannabis Policy Center, estimates the regulations will cede roughly 50% of the legal market to illicit operators—a financial and safety consequence that contradicts the stated goal of protecting consumers.

The Texas ban targets intoxicating hemp products containing more than 0.3% Delta-9 THC, products that comprise more than half of some retailers' inventory. Governor Greg Abbott vetoed a legislative ban last summer but requested increased regulation instead, handing authority to state health officials who delivered strict new rules covering child-resistant packaging, labeling, testing, and bookkeeping requirements. Edibles and beverages remain legal under these rules, as do products under the Texas Alcoholic Beverage Commission's oversight. The Legislature's original concern was preventing intoxicating hemp from reaching minors—a legitimate child safety goal. Yet Texas law permits the sale of alcohol, which kills approximately 95,000 Americans annually, with nearly 4,000 of those deaths involving individuals under age 21. 🤔 THINK ABOUT IT Cannabis has never recorded a single overdose death in human history, yet the state is eliminating zero-death products over child safety concerns while maintaining full legal access to a substance that's the leading drug-related killer of teenagers.

Texas is not alone in this regulatory pattern. Ohio's new restrictions, effective March 20, rolled back voter-approved recreational cannabis legalization by banning intoxicating hemp products and THC beverages entirely, capping extract potency at 70% THC, and criminalizing out-of-state cannabis transport. Voters had approved Issue 2 in 2023; Republican lawmakers, who promised immediate rollback, passed restrictions mostly along party lines late last year. Workers fired for using legal recreational cannabis products are now ineligible for unemployment benefits. Colorado's emerging THC beverage market—a low-dose, regulated alternative increasingly popular with consumers—faces potential federal action, according to recent reporting. These state-level reversals reflect a growing contradiction: as cannabis normalization advances in some regions, anti-cannabis politicians in others are tightening restrictions despite zero recorded deaths from cannabis consumption and documented harms from legal alternatives like alcohol and prescription opioids, which kill 16,000+ Americans annually.

The business impact is immediate and severe. Hemp retailers across Texas face inventory elimination, forced pricing adjustments, and operational costs many cannot absorb. Small operators without additional capital will shutter. Lukas Gilkey's assessment—that the regulatory scheme functions as an economic ban—aligns with market reality: when you triple licensing costs and eliminate your best-selling product category simultaneously, compliance becomes impossible for most businesses. 💰 MONEY MOVES This consolidation favors larger corporations with capital reserves while pushing consumers toward unregulated suppliers, the exact outcome state officials claim to oppose.

What makes this moment noteworthy is the timing and scale. Multiple states are simultaneously restricting hemp and cannabis access through regulatory mechanisms that achieve prohibition's effects without legislative transparency. Texas didn't technically ban smokeable hemp; it regulated the industry into collapse. Ohio reversed voter-approved legalization through legislative supermajorities. Colorado faces federal scrutiny of a legal, low-dose beverage category. Each decision cites child safety or public health—legitimate concerns—yet none address why a zero-death product faces elimination while legal alcohol and prescription drugs remain fully accessible and aggressively marketed. The pattern suggests regulatory action driven by something other than public safety data alone. 🤔 THINK ABOUT IT If the goal is genuinely child protection, why ban the only intoxicating substance with zero overdose deaths while leaving the substances that actually kill teenagers completely unregulated?

March 24, 2026

Federal health officials have released the first detailed coverage guidelines for hemp-derived CBD and THC products under a new Medicare pilot program launching April 1, allowing up to 3 milligrams of THC per product—though that threshold could shift if recent federal restrictions take effect. The Centers for Medicare & Medicaid Services announcement marks a significant moment in cannabis normalization at the federal insurance level, even as the legal landscape remains fractured. Meanwhile, Congress continues churning out competing visions for cannabis reform: sixteen bills have been filed in the 2025-2026 session, ranging from the MORE Act—which would fully deschedule marijuana and has 62 sponsors, making it the most-backed proposal—to the STATES 2.0 Act, which would prohibit federal enforcement against state-legal operations, to more targeted measures like the Hemp Planting Predictability Act, which would delay new federal hemp restrictions by three years until November 2029.

The political appetite for cannabis legality clearly exists. Yet the science is lagging behind public expectation in troubling ways. 🚀 THIS IS COOL A landmark systematic review published in The Lancet Psychiatry—the largest analysis of high-quality clinical trials on cannabis and mental health conducted over 45 years—examined more than 50 randomized-controlled trials involving nearly 2,500 patients and found no credible evidence that cannabis effectively treats anxiety, depression, or PTSD, the three conditions patients most commonly cite as reasons for medical use. The researchers determined that while insomnia, autism, and Tourette's syndrome showed some supporting data, even that evidence was graded "low quality." Lead researcher Jack Wilson from the University of Sydney told NPR that absent stronger evidence, "the routine use of medical cannabis products really should be rarely justified for the treatment of mental health disorders." The gap between what people believe cannabis does and what clinical evidence actually shows is substantial—a problem that will only close with more research funding, which has been slow to materialize even as states have legalized medical use.

🚀 THIS IS COOL On the formulation science side, researchers at East China University of Science and Technology published findings showing that powder-based CBD encapsulation using cyclodextrin dramatically outperforms traditional oil-based systems. The powder formulation retained over 90 percent of CBD under standard conditions compared to roughly 20 percent in oil when exposed to light, maintained 86-87 percent stability at elevated temperatures versus significant breakdown in oils, and generated fewer than 1 percent degradation byproducts compared to as high as 6.2 percent in oil systems. That matters because CBD degrades rapidly under heat, light, and oxygen exposure—meaning shelf life, product consistency, and actual therapeutic delivery depend heavily on how the molecule is packaged. This kind of pharmaceutical optimization is exactly what cannabis science needs more of: rigorous work on bioavailability, stability, and formulation that moves the field toward medical-grade products rather than consumer guesswork.

State-level experimentation is also accelerating. Utah Governor Spencer Cox signed legislation supporting clinical trials into psychedelic-assisted therapy for military veterans with serious mental health conditions, Georgia lawmakers passed a bill expanding medical cannabis access by allowing vaping, adding qualifying conditions, and raising THC potency limits, and Colorado's latest compliance data showed cannabis retailers achieved a 99 percent success rate on underage sales checks—suggesting that regulated legal markets can actually enforce the age restrictions that prohibition never could. 🤔 THINK ABOUT IT When alcohol kills roughly 95,000 Americans per year, prescription opioids kill over 16,000 annually, and cannabis has zero recorded overdose deaths in human history, which schedule makes sense again?

The real tension is between policy velocity and evidence velocity. Medicare coverage, sixteen congressional bills, state expansions, and international dialogue (Canada's Conservative Party leader Pierre Poilievre told Joe Rogan marijuana should be a "personal choice," despite voting against legalization) all signal normalization moving forward. But without robust clinical research—hampered for over 50 years by Schedule I classification and underfunding even after state legalization—we're building a legal cannabis economy on a foundation of modest science. The powder-based CBD breakthrough and the mental health evidence gap both point to the same problem: cannabis needs the same rigorous pharmaceutical scrutiny as any other medicine, which requires money, institutional commitment, and freedom from DEA restrictions that make controlled trials difficult to design and fund. Until that changes, public adoption will continue outpacing scientific confidence.

March 24, 2026

Texas will ban smokeable hemp cannabis products effective March 31, 2026, eliminating a market segment that represents more than 50 percent of some retailers' inventory while dramatically increasing licensing fees for both manufacturers and shops. The Texas Department of State Health Services released the new regulations earlier this month, capping total THC content at 0.3 percent and implementing child-resistant packaging, new labeling requirements, and stricter testing standards. 💰 MONEY MOVES Licensing fees for manufacturers will jump from $258 to $10,000 per facility, while retail registration costs spike from $155 to $5,000—changes industry leaders say will effectively force many small businesses to close regardless of the product restrictions themselves. Lukas Gilkey, CEO of Hometown Hero, a major hemp-derived product manufacturer, characterized the regulatory approach bluntly: "They did a ban with their own regulatory scheme. The way they wrote the rules, it's going to eliminate a lot of products that are fully legal and fully fine and not harmed anyone."

The ban affects intoxicating smokeable hemp products including pre-rolled joints and hemp flower buds, while allowing edibles and beverages to remain legal. Texas legalized hemp in 2019, defining it as containing less than 0.3 percent Delta-9 THC, but manufacturers responded by cultivating plants with higher concentrations of other cannabinoids like THC-A to deliver intoxicating effects within the legal framework. The Texas Legislature originally voted to ban these products citing child safety concerns, but Governor Greg Abbott vetoed that decision last summer and instead directed the Alcoholic Beverage Commission and DSHS to increase regulations. Some San Antonio retailers have already begun closing their doors ahead of the deadline, anticipating the financial impact of the fee increases alone.

🤔 THINK ABOUT IT Heather Fazio, director of the Texas Cannabis Policy Center, estimates the ban will hand approximately 50 percent of the legal market to illicit operators, potentially making the state less safe rather than safer. The regulatory approach creates a peculiar outcome: consumers seeking smokeable hemp products will either stop purchasing legally or turn to unregulated sources, neither of which serves the stated child-protection objective. The ban also impacts a customer base that extends beyond recreational users—veterans in particular rely on legal THC products for PTSD, chronic pain, and anxiety management, and the elimination of smokeable options removes a preferred consumption method without offering equivalent alternatives.

An East Texas vape shop has already filed suit to block the new hemp rules, signaling that legal challenges will likely delay or modify implementation. The March 31 deadline remains firm as of now, but the litigation could reshape how Texas enforces these restrictions. Industry groups and individual retailers across San Antonio and beyond are mobilizing to either fight the rules or prepare for the transition, creating uncertainty for businesses that have operated legally under the previous regulatory framework for years.